The third Sustainable Development Goal (SDG), to ensure healthy lives and promote well-
being for all at all ages, has particular relevance and implementation challenges amongst …

Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) is a new CFTR (Cystic Fibrosis
Transmembrane Conductance Regulator) modulator treatment, used over the last few years …

Background Although people living with cystic fibrosis (PwCF) often have some risk factors
for cardiovascular disease, including diabetes and chronic inflammation, little is known …

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is the newest cystic fibrosis
transmembrane conductance regulator (CFTR) modulator drug approved for the treatment of …

Rationale Studies estimating the rate of lung function decline in cystic fibrosis have been
inconsistent regarding the methods used. How the methodology used impacts the validity of …

Defective CFTR biogenesis and activity in cystic fibrosis airways leads to airway dehydration
and impaired mucociliary clearance, resulting in chronic airway infection and inflammation …

People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal
symptoms throughout life. There is evidence indicating interaction between the microbiota …

With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective
cystic fibrosis transmembrane conductance regulator (CFTR) therapy, the clinical spectrum …

The airways of people with cystic fibrosis (CF) often harbor a diverse microbiota and in
recent years, much effort has been invested in cataloguing these. In spite of providing a …

Background CFTR modulator therapies have positive clinical outcomes, yet chronic
inflammation and bacterial infections persist in people with CF (pwCF). How elexacaftor …